- Home
- HYI vs UNCY Comparison
HYI vs UNCY Comparison
Compare HYI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYI | UNCY |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.2M | 145.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYI | UNCY |
|---|---|---|
| Price | $10.65 | $5.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 62.5K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.44 | $3.72 |
| 52 Week High | $12.12 | $8.74 |
Technical Indicators
Market Signals| Indicator | HYI | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 40.44 |
| Support Level | $10.46 | $4.11 |
| Resistance Level | $10.67 | $7.48 |
| Average True Range (ATR) | 0.07 | 0.79 |
| MACD | 0.01 | -0.23 |
| Stochastic Oscillator | 64.03 | 38.88 |
Price Performance
Historical ComparisonAbout HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.